



## Recent Advancements in the Diagnosis, Prevention of Drug Therapy-COVID-19

Kumud Joshi\*

Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India

\*Corresponding author: Kumud Joshi, Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India, E-Mail: kumudjoshi26@gmail.com

Received date: May 03, 2021; Accepted date: May 18, 2021;

Published date: May 25, 2021

### Description

Severe acute metabolism syndrome coronavirus (CoV)-2 (SARS-CoV-2), antecedently referred to as 2019 novel CoV, emerged from China in late December 2019. This virus causes CoV disease-19 (COVID-19), that has been tried a world pandemic resulting in a serious occurrence. CoVs cause sicknesses that point severity from the communicable disease to severe metabolism sicknesses and death. notwithstanding, with technological advances and imperative lessons gained from previous outbreaks, mankind is best outfitted to take care of the most recent rising cluster of CoVs. Studies on the event of in vitro diagnostic tests, vaccines, and drug re-purposing square measure being administered during this field. Currently, no approved treatment is offered for SARS-CoV-2 given the shortage of proof. CoVs square measure a extremely varied cluster of positive-sense, enclosed fiber ribonucleic acid viruses. They cause varied diseases regarding metabolism, hepatic, medicine, and enteric systems of assorted severity amongst humans and animals.

Different human CoVs, as well as HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1, cause an occasional incidence of metabolism infections and delicate malady. However, within the past many years, 2 deadly strains of CoVs, namely, Middle-East metabolism syndrome CoV (MERS-CoV) and SARS-CoV have emerged, inflicting severe infections in humans. The causative infective agent of COVID-19 is 2019-nCoV, that was initial detected in Gregorian calendar month 2020 and later termed as SARS-CoV-2. This infective agent may be a fiber ribonucleic acid virus that most likely originated from barmy because of its similar genetic sequence to different CoVs. though SARS-CoV-2 shares genetic options attuned with the opposite members of the CoV family, it possesses significantly varied genetic sequence compared therewith of earlier sequenced CoVs. SARS-CoV-2 shares around seventy nine.5% identical genetic sequence with SARS-CoV and ninety six.2% genetic sequence similarity with RaTG13, a brief ribonucleic acid-dependent RNA enzyme (RdRp) region gift within the CoV that originated from barmy.

Most of the COVID-19 patients square measure aged 30–79 years recent with a mean vary of 49–59 years, and comparatively fewer cases square measure reported in youngsters below fifteen years. Male patients represent over half the reported cases, as well as those with one or a lot of synchronic medical complications, like polygenic disorder, high blood pressure, vessel disorders, or cancer. In 7–27.8% of the patients littered with COVID-19, troponin levels square measure elevated and will be concerned in vessel disorders, like sort I infarction, decompensated cardiopathy or heart disease.

Thus far, the WHO has approved 3 techniques for the detection of CoVs. within the reverse transcription-polymerase chain reaction (RT-PCR) assay for respiratory disorder virus, clinical specimens from cavity or cavity samples square measure obtained, and 3 genes square measure targeted. These targets embrace the Orf1b factor (human ribonucleic acid enzyme protein), N-gene (N protein), and also the E-gene (E protein). many PCR kits supported RT-PCR or quantitative RT-PCR ways square measure out there within the market. The bioassay victimisation enzyme-linked immunosorbent assay (ELISA) is a smaller amount expensive however is additionally less sensitive than PCR. SARS-CoV-2 is confirmed by the presence of immune globulin (Ig) G in technique assay (IFA) medical science tests square measure blood-based tests that establish whether or not the tested person is exposed to associate infection.

These tests square measure supported the presence of antibodies for a specific infective agent acting as antigens. These antigens square measure recognized by the system of the infected person as foreign bodies and develop specific antibodies to fight the infection. only if SARS-CoV-2 may be a novel virus, and also the antibodies developed by the system of infected individuals square measure specific and solely gift in individuals with COVID-19, these antibodies will act as markers for the malady.

Citation: Joshi K (2021) Recent Advancements in the Diagnosis, Prevention of Drug Therapy-COVID-19. J Pharm Drug Deliv Res 10:5.